精准免疫新标杆丨K药将再添一线治疗重磅适应证( 三 )

期待K药为更多中国消化道肿瘤患者带来长生存，甚至临床治愈！
参考文献：
1.Thierry Andre, First-line therapy of pembrolizumab versus standard of care (SOC) in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase III, KEYNOTE-177 study. ASCO 2020, LBA4
2.KK Shiu ， T Andre ， TW Kim ， BV Jensen ， LA Diaz, KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer, ASCO GI 2021
3.Reck M., KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50%, ESMO, 2016 Abstract 4370
4.Rischin et al., Protocol-Specified Final Results of the KEYNOTE-048 Trial of Pembrolizumab as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC）， ASCO, 2019, Oral Abstract 6000
5.Thierry Andre et al., Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). 2021 ASCO Abstract 3500, www.asco.org

精准免疫新标杆 丨K药将再添一线治疗重磅适应证( 三 )

精准免疫新标杆丨K药将再添一线治疗重磅适应证( 三 )